Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, Jiangsu Province 210009, People's Republic of China,
Int J Nanomedicine. 2019 Apr 8;14:2465-2483. doi: 10.2147/IJN.S195828. eCollection 2019.
Antigen-presenting cells (APCs) are powerful tools to expand antigen-specific T cells ex vivo and in vivo for tumor immunotherapy, but suffer from time-consuming generation and biosafety concerns raised by live cells. Alternatively, the cell-free artificial antigen-presenting cells (aAPCs) have been rapidly developed. Nanoscale aAPCs are recently proposed owing to their superior biodistribution and reduced embolism than conventional cell-sized aAPCs, but pose the challenges: easier cellular uptake and smaller contact surface area with T cells than the cell-sized counterparts. This study aimed to fabricate a new "stealth" nano-aAPCs with microscale contact surface area to minimize cellular uptake and activate antigen-specific T cells by combination uses of ellipsoidal stretch, PEGylation, and self-marker CD47-Fc conjugation.
The spherical polylactic-co-glycolic acid nanoparticles were fabricated using a double-emulsion method, and then stretched twofold using film-stretching procedure followed by PEGylation and co-coupling with CD47-Fc, H-2K/TRP2-Ig dimers, and anti-CD28. The resulting PEGylated and CD47-conjugated nanoellipsoidal aAPCs (EaAPC) were co-cultured with macrophages or spleen lymphocytes and also infused into melanoma-bearing mice. The in vitro and in vivo effects were evaluated and compared with the nanospherical aAPCs (SaAPC), nanoellipsoidal aAPCs (EaAPC), or PEGylated nanoellipsoidal aAPC (EaAPC).
EaAPC markedly reduced cellular uptake in vitro and in vivo, as compared with EaAPC, EaAPC, SaAPC, and Blank-NPs and expanded naïve TRP2-specific CD8 T cells in the co-cultures with spleen lymphocytes. After three infusions, the EaAPC showed much stronger effects on facilitating TRP2-specific CD8 T-cell proliferation, local infiltration, and tumor necrosis in the melanoma-bearing mice and on inhibiting tumor growth than the control aAPCs.
The superimposed or synergistic effects of ellipsoidal stretch, PEGylation, and CD47-Fc conjugation minimized cellular uptake of nano-aAPCs and enhanced their functionality to expand antigen-specific T cells and inhibit tumor growth, thus suggesting a more valuable strategy to design "stealth" nanoscale aAPCs suitable for tumor active immunotherapy.
抗原呈递细胞 (APC) 是体外和体内扩增抗原特异性 T 细胞用于肿瘤免疫治疗的有力工具,但由于活细胞的生成耗时和生物安全性问题而受到限制。相反,无细胞的人工抗原呈递细胞 (aAPC) 已经得到了快速发展。由于纳米级 aAPC 具有优于传统细胞大小 aAPC 的更好的生物分布和减少栓塞的特性,因此最近提出了纳米级 aAPC,但也存在一些挑战:与细胞大小的对应物相比,更容易被细胞摄取,并且与 T 细胞的接触表面积更小。本研究旨在通过使用椭圆形拉伸、聚乙二醇化和自标记 CD47-Fc 偶联来制造具有微接触表面积的新型“隐形”纳米级 aAPC,以最小化细胞摄取并激活抗原特异性 T 细胞。
使用双乳液法制备球形聚乳酸-聚乙二醇酸纳米颗粒,然后使用薄膜拉伸程序将其拉伸两倍,再进行聚乙二醇化并与 CD47-Fc、H-2K/TRP2-Ig 二聚体和抗 CD28 偶联。将得到的聚乙二醇化和 CD47 偶联的纳米椭圆形 aAPC(EaAPC)与巨噬细胞或脾淋巴细胞共培养,并注入黑色素瘤荷瘤小鼠体内。评估并比较了其与纳米球形 aAPC(SaAPC)、纳米椭圆形 aAPC(EaAPC)或聚乙二醇化纳米椭圆形 aAPC(EaAPC)的体外和体内效果。
与 EaAPC、EaAPC、SaAPC 和空白 NPs 相比,EaAPC 在体外和体内均显著降低了细胞摄取,并且在与脾淋巴细胞的共培养中扩增了幼稚的 TRP2 特异性 CD8 T 细胞。经过三次输注,EaAPC 对促进 TRP2 特异性 CD8 T 细胞增殖、局部浸润和肿瘤坏死以及抑制肿瘤生长的作用明显强于对照 aAPC。
椭圆形拉伸、聚乙二醇化和 CD47-Fc 偶联的叠加或协同作用可最大程度地减少纳米 aAPC 的细胞摄取,并增强其功能以扩增抗原特异性 T 细胞并抑制肿瘤生长,因此提示了一种更有价值的策略来设计适合肿瘤主动免疫治疗的“隐形”纳米级 aAPC。